Measuring immune response to COVID-19 in patients with weakened immune systems
Official title: Implementation of a qPCR-based assay for the quantification of SARS-CoV-2-specific T cells in immunocompromised patients
Funded at Icahn School of Medicine at Mount Sinai · NIH-11191768 · Data updated 2026-11-12
This study is looking at a new way to check how well the immune system responds to the COVID-19 virus in people with Multiple Myeloma, a type of blood cancer that can weaken immunity, to help improve their care and treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 18, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $350,358 |
| NIH project number | 4UH3CA271390-02 |
| Project ID | NIH-11191768 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Multiple Myeloma who are at risk of severe COVID-19 due to their compromised immune systems.
✕Less likely to help
Patients who do not have Multiple Myeloma or other similar immunocompromising conditions may not benefit from this research.
What this research studies
This research focuses on developing a new method to measure the immune response to SARS-CoV-2 in patients with Multiple Myeloma, a type of blood cancer that weakens the immune system. The approach involves using a qPCR-based assay to quantify specific T cells that respond to the virus, which is crucial for understanding how well these patients can fight off infections. By analyzing blood samples from these patients, the study aims to provide insights into their cellular immunity, which is often overlooked in traditional testing methods. This could lead to better monitoring and treatment strategies for immunocompromised individuals.
Why it matters
Potential benefit: If successful, this research could enhance the ability to monitor and improve immune responses in patients with weakened immune systems, leading to better health outcomes.
How similar studies have gone: Other research has shown promise in using similar qPCR-based methods to assess immune responses, indicating that this approach could be effective.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Guccione, Ernesto — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guccione, Ernesto
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.